hPD-L1

品系全名

C57BL/6JSmo-Cd274tm1(hPD-L1)Smoc

目录号

NM-HU-00062

品系状态

活体

导出PDF

基因信息

基因名
Cd274

品系描述

通过同源重组,将小鼠基因Cd274进行人源化修饰。与此相似的品系还有hPD-L1(2)(NM-HU-190039),详细信息请咨询技术顾问。
应用领域:免疫治疗;肿瘤研究;药物筛选

验证数据

image.png

Fig1.Expression of PD-L1 in the spleen lymphocytes collected from homozygous humanized PD-L1 mice and wild-type mice is detected by FACS. The results showed that the expression of human PD-L1 can be detected in both T cells and B cells collected from the spleen of homozygous humanized PD-L1 mice. (Completed in collaboration with CrownBio)

image.png

Fig2. Immunotype in blood , spleen and bone marrow in hPD-L1 mice.  

image.png


Fig3. Immunotype in blood in hPD-L1 mice. 

image.png

Fig4. Immunotype in spleen in hPD-L1 mice. 

image.png

Fig5. Immunotype in bone marrow in hPD-L1 mice. 

image.png

Fig6. In vivo validation of anti-tumor efficacy in a MC38 tumor-bearing model of humanized PD-L1 mice. Homozygous humanized PD-L1 mice were inoculated with MC38 colon cancer cells (expressing human PDL1 rather than murine PD-L1). After the tumors grew to 100 mm3, the animals were randomly assigned into a control group and a treatment group (n=5). The results showed: The antibodies targeting human PD-L1 were associated with a very significant anti-tumor effect (TGI: tumor growth inhibition, p < 0.001), demonstrating that the humanized PD-L1 mice are a good in vivo model for validating the efficacy of antibodies targeting human PD-L1.


发表文献 9篇

1. Intratumoural vaccination via checkpoint degradation-coupled antigen presentation
发表年份:2026 来源杂志:NATURE

2. High-Affinity Decoy PD-1 Mutant Screened from an Epitope-Specific Cell Library
发表年份:2021 来源杂志:Engineering

3. Dose escalation biodistribution, positron emission tomography/computed tomography imaging and dosimetry of a highly specific radionuclide-labeled non-blocking nanobody
发表年份:2021 来源杂志:EJNMMI Research

4. Therapeutic Effect of an Anti-Human Programmed Death-Ligand 1 (PD-L1) Nanobody on Polymicrobial Sepsis in Humanized Mice
发表年份:2021 来源杂志:MEDICAL SCIENCE MONITOR

5. Discovery of novel CA-4 analogs as dual inhibitors of tubulin polymerization and PD-1/PD-L1 interaction for cancer treatment
发表年份:2020 来源杂志:EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

6. A Novel Bispecific Antibody with PD-L1–assisted OX40 Activation for Cancer Treatment
发表年份:2020 来源杂志:MOLECULAR CANCER THERAPEUTICS

7. Anticancer Effect of Salvia plebeia and Its Active Compound by Improving T-Cell Activity via Blockade of PD-1/PD-L1 Interaction in Humanized PD-1 Mouse Model
发表年份:2020 来源杂志:Frontiers in Immunology

8. Unripe Black Raspberry (Rubus coreanus Miquel) Extract and Its Constitute, Ellagic Acid Induces T Cell Activation and Antitumor Immunity by Blocking PD-1/PD-L1 Interaction
发表年份:2020 来源杂志:Foods

9. Distinct contribution of PD-L1 suppression by spatial expression of PD-L1 on tumor and non-tumor cells
发表年份:2018 来源杂志:Cellular & Molecular Immunology

展开

你也可能感兴趣

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

查看

Workshop:Progress and Advances in Preclinical immuno-Oncology Research

SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.

查看

Customizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!

At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.

查看